Healthcare provider stigma toward patients with substance use disorders.
Background and aims: The overdose epidemic accounts for more than 89 000 deaths across the United States annually. Despite the availability of medications and therapies to treat substance use disorders (SUD), most people remain untreated. Stigma towards treating patients with SUD has been identified...
| Publicado en: | Addiction Vol. 120; no. 10; pp. 2005 - 2020 |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Oct2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=187948810&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 187948810 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09652140 AIO jtl: Addiction issn: 09652140 maglogo: Y pubinfo: dt: Oct2025 vid: 120 iid: 10 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 187948810 186833088 187948810 187948810 10.1111/add.70122 187948810 ppf: 2005 ppct: 15 formats: fmt: – @attributes: type: T – @attributes: type: C – @attributes: type: P tig: atl: Healthcare provider stigma toward patients with substance use disorders. aug: au: Parish, Carrigan L. Feaster, Daniel J. Pollack, Harold A. Horigian, Viviana E. Wang, Xiaoming Jacobs, Petra Pereyra, Margaret R. Drymon, Christina Allen, Elizabeth Gooden, Lauren K. del Rio, Carlos Metsch, Lisa R. affil: Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, Miami Research Center, Miami FL,, USA sug: subj: Health Personnel Psychosocial Factors Stigma Evaluation Substance Use Disorders Psychosocial Factors Attitude of Health Personnel Evaluation Persons with Substance Use Disorders Human Funding Source United States Male Female Adult Middle Age Probability Questionnaires Random Sample Physicians, Family Physicians, Emergency Dentists Analgesics, Opioid Heroin Fentanyl Methamphetamine Cocaine Alcoholism Descriptive Statistics Data Analysis Software Ajzen's Theory of Planned Behavior Repeated Measures Post Hoc Analysis Social Distancing Diabetes Mellitus, Type 2 Health Care Delivery Confidence Intervals Scales Adult: 19-44 years Middle Aged: 45-64 years Male Female ab: Background and aims: The overdose epidemic accounts for more than 89 000 deaths across the United States annually. Despite the availability of medications and therapies to treat substance use disorders (SUD), most people remain untreated. Stigma towards treating patients with SUD has been identified as a potential barrier to SUD treatment. This study aimed to quantify the prevalence and intensity of provider stigma towards patients with SUD, by substance use type and compared with other conditions, and its relationship to providers' clinical practices. Design: National probability sample survey (October 2020–October 2022). Setting: USA; online/paper questionnaire. Participants: Primary care (PCPs) and emergency medicine physicians (EMPs) and dentists randomly selected from the American Medical and Dental Associations. Data were collected from 1240 participants (Council of American Survey Research Organizations response rate 53.6%). Measurements The main outcome was self‐reported provider stigma towards people with SUD, assessed by the Medical Condition Regard Scale. Providers indicated their agreement with 11 statements concerning three SUD categories [opioids (OUD), stimulants, alcohol (AUD)], Type II diabetes, depressive disorder and HIV. Mixed models compared stigma levels across conditions and by clinician group. Clinicians were assessed about their screening, referral and treatment practices. Findings The lowest stigma rating was for diabetes (mean = 23.2; standard deviation = 6.5) and the highest for stimulant use disorders (mean = 36.3; standard deviation = 10.7). Stigma towards OUD was statistically significantly higher than AUD [effect size (ES) = 0.49, 95% confidence interval (CI) = (0.42–0.57), P < 0.001], while stigma towards stimulant use disorders was statistically significantly higher than OUD [ES = 0.11, 95% CI = (−0.04 to 0.19), P < 0.004]. EMPs had statistically significantly higher stigma scores than PCPs (P < 0.001), while PCPs reported significantly higher stigma scores than did dentists (P < 0.014). Lower stigma scores were associated with provision of SUD referrals [ES = −0.37, 95% CI = (−0.66 to −0.07)], providing medications for OUD [stigma scores: AUD (ES = ‐0.44, 95% CI = [−0.73 to −0.15]), OUD (ES = −1.26, 95% CI = [−1.55 to −0.97]) and stimulant use disorder (ES = −0.73, 95% CI = [−1.02 to −0.44])] and having available SUD consultation [stigma scores: AUD (ES = −0.48, 95% CI = [−0.67 to −0.28]), OUD (ES = −0.51, 95% CI = [−0.86 to −0.37]) and stimulant use disorder (ES = −0.59, 95% CI = [−0.78 to −0.39])]. Conclusions: Among US primary care and emergency medicine physician workforces, provider stigma towards substance use disorders appears to be higher than for opioid, stimulant and alcohol use disorders and negatively associated with providers' clinical practices. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|